ET receptor antagonists bosentan, ambrisentan and macitentan are currently approved for the treatment of pulmonary hypertension, based upon the proposed pathogenesis of this disease, which is characterized by enhanced synthesis of ET-1 and progressive proliferation and hypertrophy of smooth muscle cells in the pulmonary vasculature. This evidence concerns the gene EDN1 and pulmonary arterial hypertension.